WA
NBIX icon

Waverly Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Waverly Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860K Sell
5,102
-64
-1% -$9.49K 0.01% 947
2026
Q1 		$681K Buy
5,166
+693
+15% +$92K 0.01% 944
2025
Q4 		$634K Buy
4,473
+952
+27% +$138K 0.01% 913
2025
Q3 		$494K Buy
3,521
+1,920
+120% +$260K ﹤0.01% 851
2025
Q2 		$201K Buy
+1,601
New +$184K ﹤0.01% 1125

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Waverly Advisors's NBIX Position: Q2 2026 in Review

Waverly Advisors reduced its Neurocrine Biosciences (NBIX) stake by 1.2% in Q2 2026, selling an estimated $9.49K and leaving 5,102 shares worth $860K. The position accounts for 0.01% of the portfolio, ranked #947.

Waverly Advisors first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Waverly Advisors held 5,102 shares of Neurocrine Biosciences worth $860K as of Q2 2026.
  • Waverly Advisors sold 64 Neurocrine Biosciences shares in Q2 2026, an estimated $9.49K.
  • Neurocrine Biosciences made up 0.01% of Waverly Advisors's portfolio in Q2 2026, its #947 holding.
  • Waverly Advisors first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Waverly Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.